Profile
Stephen Farrand formerly worked at Merck & Co., Inc., as Vice President-Bioprocess Development from 2009 to 2015, NantKwest, Inc., as Senior Vice President-Global Manufacturing from 2015 to 2016, Schering-Plough Research Institute, as VP-Global Biologics & Sterile Product Development, and Jounce Therapeutics, Inc., as Chief Technical Officer.
Dr. Farrand received his undergraduate degree from the University of Bath and doctorate degree from the University of Leicester.
Former positions of Stephen Farrand
| Companies | Position | End |
|---|---|---|
| IMMUNITYBIO, INC. | Corporate Officer/Principal | 01/01/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2015 |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Corporate Officer/Principal | - |
| JOUNCE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Stephen Farrand
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
NantKwest, Inc.
NantKwest, Inc. BiotechnologyHealth Technology Develops and produces cancer treatment products | Health Technology |
University of Bath
University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leicester
University of Leicester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Health Technology |
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immunotherapy company that develops therapies to treat cancer | Health Technology |
- Stock Market
- Insiders
- Stephen Farrand
















